Santos-Filho Admário S, Triginelli Sérgio Augusto, Traiman Paulo, Cunha-Melo José Renan, Silva-Filho Agnaldo L
Department of Obstetrics and Gynecology, School of Medicine, Federal University of Minas Gerais, Avenida Professor Alfredo Balena 190, Santa Efigênia, 30130100 Belo Horizonte, MG, Brazil.
Arch Gynecol Obstet. 2007 Jan;275(1):13-7. doi: 10.1007/s00404-006-0206-3. Epub 2006 Jul 21.
This study was undertaken to evaluate the association between the telomerase activity in the tumor and clinicopathological findings in patients with stage IB-IIA (FIGO) carcinoma of the cervix.
Thirty-eight patients with carcinoma of the cervix submitted to radical hysterectomy were prospectively from January 1998 to November 2001. Samples from the tumor were taken and analyzed by the telomerase PCR-TRAP-ELISA kit. Clinicopathological characteristics such as age, stage, tumor size, grade of differentiation, lymphatic vascular space invasion (LVSI), parametrial involvement and status of pelvic lymph nodes were also recorded.
Patient's mean age was 49.3+/-1.99 years (29-76 years). The clinical stage (FIGO) was IB in 35 patients (92.1%) and IIA in 3 patients (7.9%). The histological classification identified squamous cell carcinoma in 33 patients (86.8%) and adenocarcinoma in 5 patients (13.2%). There was no association between age, clinical stage, histological classification, tumor size, grade of differentiation and presence of LVSI with tumoral telomerase activity. The telomerase activity was not associated with the presence of vaginal involvement (P=0.349), parametrium involvement (P=0.916), pelvic lymph node metastasis (P=0.988) or tumoral recurrence (P=0.328) in patients with carcinoma of the cervix.
Telomerase activity in the tumor is not associated with clinicopathological findings or tumor recurrence in patients with early stage cervical carcinoma.
本研究旨在评估IB-IIA期(国际妇产科联盟[FIGO])宫颈癌患者肿瘤中的端粒酶活性与临床病理特征之间的关联。
1998年1月至2001年11月,对38例行根治性子宫切除术的宫颈癌患者进行前瞻性研究。采集肿瘤样本,并用端粒酶PCR-TRAP-ELISA试剂盒进行分析。同时记录患者的年龄、分期、肿瘤大小、分化程度、淋巴血管间隙浸润(LVSI)、宫旁组织受累情况及盆腔淋巴结状态等临床病理特征。
患者的平均年龄为49.3±1.99岁(29 - 76岁)。临床分期(FIGO)为IB期的患者有35例(92.1%),IIA期的患者有3例(7.9%)。组织学分类显示,33例(86.8%)为鳞状细胞癌,5例(13.2%)为腺癌。年龄、临床分期、组织学分类、肿瘤大小、分化程度及LVSI的存在与肿瘤端粒酶活性之间均无关联。在宫颈癌患者中,端粒酶活性与阴道受累(P = 0.349)、宫旁组织受累(P = 0.916)、盆腔淋巴结转移(P = 0.988)或肿瘤复发(P = 0.328)均无关联。
早期宫颈癌患者肿瘤中的端粒酶活性与临床病理特征或肿瘤复发无关。